Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy
JAMA · 17.10.2023 · 330 (15) · 1448
DOI: 10.1001/jama.2023.18688 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, erschienen am 17.10.2023. Verfasst von Teresa Coelho und 30 weiteren Autor:innen. Beteiligte Einrichtung: Centro Hospitalar Universitário de Santo António, Porto, Portugal. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Polyneuropathies. Die Arbeit wurde bisher 259-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS.
Abstract (Originalsprache)
Importance Transthyretin gene silencing is an emerging treatment strategy for hereditary transthyretin (ATTRv) amyloidosis.
Objective
To evaluate eplontersen, an investigational ligand-conjugated antisense oligonucleotide, in ATTRv polyneuropathy. Design, Setting, and Participants NEURO-TTRansform was an open-label, single-group, phase 3 trial conducted at 40 sites across 15 countries (December 2019-April 2023) in 168 adults with Coutinho stage 1 or 2 ATTRv polyneuropathy, Neuropathy Impairment Score 10-130, and a documented TTR variant. Patients treated with placebo from NEURO-TTR ( NCT01737398 ; March 2013–November 2017), an inotersen trial with similar eligibility criteria and end points, served as a historical placebo (“placebo”) group.
Interventions
Subcutaneous eplontersen (45 mg every 4 weeks; n = 144); a small reference group received subcutaneous inotersen (300 mg weekly; n = 24); subcutaneous placebo weekly (in NEURO-TTR; n = 60). Main Outcomes and Measures Primary efficacy end points at week 65/66 were changes from baseline in serum transthyretin concentration, modified Neuropathy Impairment Score +7 (mNIS+7) composite score (scoring range, –22.3 to 346.3; higher scores indicate poorer function), and Norfolk Quality of Life Questionnaire–Diabetic Neuropathy (Norfolk QoL-DN) total score (scoring range, –4 to 136; higher scores indicate poorer quality of life). Analyses of efficacy end points were based on a mixed-effects model with repeated measures adjusted by propensity score weights.
Results
Among 144 eplontersen-treated patients (mean age, 53.0 years; 69% male), 136 (94.4%) completed week-66 follow-up; among 60 placebo patients (mean age, 59.5 years; 68% male), 52 (86.7%) completed week-66 follow-up. At week 65, adjusted mean percentage reduction in serum transthyretin was −81.7% with eplontersen and −11.2% with placebo (difference, −70.4% [95% CI, −75.2% to −65.7%]; P < .001). Adjusted mean change from baseline to week 66 was lower (better) with eplontersen vs placebo for mNIS+7 composite score (0.3 vs 25.1; difference, −24.8 [95% CI, −31.0 to −18.6; P < .001) and for Norfolk QoL-DN (−5.5 vs 14.2; difference, −19.7 [95% CI, −25.6 to −13.8]; P < .001). Adverse events by week 66 that led to study drug discontinuation occurred in 6 patients (4%) in the eplontersen group vs 2 (3%) in the placebo group. Through week 66, there were 2 deaths in the eplontersen group consistent with known disease-related sequelae (cardiac arrhythmia; intracerebral hemorrhage); there were no deaths in the placebo group. Conclusions and Relevance In patients with ATTRv polyneuropathy, the eplontersen treatment group demonstrated changes consistent with significantly lowered serum transthyretin concentration, less neuropathy impairment, and better quality of life compared with a historical placebo. Trial Registration ClinicalTrials.gov Identifier: NCT04136184 ; EU Clinical Trials Register: EudraCT 2019-001698-10
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centro Hospitalar Universitário de Santo António, Porto, Portugal.
- Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto, Ribeirão Preto, Brazil.
- Indiana University School of Medicine, Indianapolis.
- National Taiwan University Hospital, Taipei, Taiwan.
- İstanbul Üniversitesi-Istanbul Tıp Fakültesi, Istanbul, Turkey.
- Universidade Estadual de Campinas, Campinas, São Paulo, Brazil.
Förderung
- NCATS NIH HHS
Zitieren
APA
Coelho, T., Marques, W., Dasgupta, N. R., Chao, C. C., Parman, Y., França, M. C., Guo, Y. C., Wixner, J., Ro, L. S., Calandra, C. R., Kowacs, P. A., Berk, J. L., Obici, L., Barroso, F. A., Weiler, M., Conceição, I., Jung, S. W., Buchele, G., Brambatti, M., …, & NEURO-TTRansform Investigators (2023). Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy. JAMA, 330(15), 1448. https://doi.org/10.1001/jama.2023.18688
Vancouver
Coelho T, Marques W, Dasgupta NR, Chao CC, Parman Y, França MC, et al. Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy. JAMA. 2023;330(15):1448. doi:10.1001/jama.2023.18688
BibTeX
@article{Coelho2023,
author = {Coelho, Teresa and Marques, Wilson and Dasgupta, Noel R and Chao, Chi-Chao and Parman, Yesim and França, Marcondes Cavalcante and Guo, Yuh-Cherng and Wixner, Jonas and Ro, Long-Sun and Calandra, Cristian R and Kowacs, Pedro A and Berk, John L and Obici, Laura and Barroso, Fabio A and Weiler, Markus and Conceição, Isabel and Jung, Shiangtung W and Buchele, Gustavo and Brambatti, Michela and Chen, Jersey and Hughes, Steven G and Schneider, Eugene and Viney, Nicholas J and Masri, Ahmad and Gertz, Morie R and Ando, Yukio and Gillmore, Julian D and Khella, Sami and Dyck, P James B and Waddington Cruz, Márcia and NEURO-TTRansform Investigators, NEURO-TTRansform Investigators},
title = {Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy},
journal = {JAMA},
year = {2023},
volume = {330},
number = {15},
pages = {1448},
doi = {10.1001/jama.2023.18688}
}
EUVIMED